LYRA THERAPEUTICS INC

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 15:01:58 By Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

15 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

27 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

14 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

21 May 2024 08:14:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

06 May 2024 06:59:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

30 Apr 2024 15:04:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 Apr 2024 15:51:11 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

21 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

16 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

12 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

06 Sep 2023 14:00:28 By Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

29 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

13 Jul 2023 06:30:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present at Jefferies Healthcare Conference

02 Jun 2023 06:30:00 By Nasdaq GlobeNewswire